CTX-009
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Trial Timeline
Dec 8, 2022 → May 15, 2025
NCT ID
NCT05513742About CTX-009
CTX-009 is a phase 2 stage product being developed by Compass Therapeutics for Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05513742. Target conditions include Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05513742 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Colorectal Cancer